In the present study, we propose a predictive model that includes age, sex, underlying disease, CD34+ cell count in the graft, and cumulative dose of corticosteroids during the pre-engraftment phase for refractory/recurrent CMV infection after HID HSCT for the prediction of total CMV infection, mortality, and survival after HID HSCT. The gene discussed is CD34; the disease is cytomegalovirus infection.